New treatment strategies in ALL. B lymphoblasts express the cell surface antigens CD19, CD20, and CD22, which are targets for the antibody therapies blinatumomab, rituximab, and inotuzumab. A subset of patients with B-ALL (20%-25%) express the Ph-like signature. These patients may be candidates for clinical trials with TKI–based therapy. Bcl-2 is overexpressed in both B- and T-ALL, and current trials are evaluating the bcl-2 inhibitor venetoclax in R/R disease.